A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in Participants with HIV-1 Virologically Suppressed on Biktarvymidwayadmin2020-11-03T20:00:39+00:00
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in Participants with HIV-1 Virologically Suppressed on Biktarvy
MK8591A-018 · Trial ·
Major Inclusion/Exclusion Criteria:
- Currently on Biktarvy for at least 3 months
- HIV RNA <50 while on Biktarvy
- CD4 >100